A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-07-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: time oflifeacuteto assessthe time
  Phrases that lowered it: healthyparticipantsperiodparticipantmale
• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 11.4% (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 83 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1019 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.2% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 73.1% (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) NCT05797701 · started 2021 · scored riskier than 0% of active trials completed
• Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects NCT06064539 · started 2020 · scored riskier than 1% of active trials completed
• Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants NCT05795907 · started 2020 · scored riskier than 7% of active trials completed
• Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine NCT05486949 · started 2022 · scored riskier than 2% of active trials completed
• Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 NCT03376529 · started 2017 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.